1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Factbox-GSK's consumer health business

01/15/2022 | 09:48am EDT
FILE PHOTO: The GlaxoSmithKline building in Hounslow, west London

(Reuters) - Consumer goods giant Unilever has approached GlaxoSmithKline about buying the pharmaceutical group's consumer goods arm, after a newspaper reported that a 50 billion-pound ($68.4 billion) bid it made had been rebuffed.

GSK declined to comment on the approach which would be an alternative to its plans to list the business separately on the London Stock Exchange this year.

BRANDS:

The consumer goods business, in which U.S. pharmaceuticals company Pfizer owns a 32% stake, includes brands such as Sensodyne and parodontax toothpaste, painrelief treatments Advil, Voltaren and Panadol, Otrivin nasal spray, cold and flu medicine Theraflu and Centrum vitamins.

GSK and Pfizer folded together their consumer health businesses in a deal completed in 2019.

GSK had struck a $13 billion deal the previous year to buy full control of a consumer health venture with Swiss drugs group Novartis.

MAIN MARKETS:

GSK describes itself as are one of the world's leading over-the-counter (OTC) healthcare companies with number one positions in markets including the United States, India and Germany.

Its rivals include Johnson & Johnson, Bayer and Sanofi.

TURNOVER:

The business generated sales of 10 billion pounds ($13.7 billion) in 2020.

GSK, whose two other main divisions are pharmaceuticals and vaccines, had turnover of 34 billion pounds that year.

MANAGEMENT:

Dave Lewis, former chief executive of British supermarket group Tesco, has been appointed to chair the business when it is spun off.

Brian McNamara will be its chief executive, a position he has held since 2016 within the business as part of GSK.

The demerged company is planning to build a new headquarters at Weybridge in southern England.

($1 = 0.7314 pounds)

(Editing by Keith Weir and David Evans)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 0.77% 63.78 Delayed Quote.34.66%
GLAXOSMITHKLINE PLC -0.39% 1775 Delayed Quote.10.92%
LONDON STOCK EXCHANGE PLC 0.11% 7314 Delayed Quote.5.43%
NOVARTIS AG 0.16% 87.82 Delayed Quote.9.22%
ON SEMICONDUCTOR CORPORATION 3.19% 56.24 Delayed Quote.-19.76%
PFIZER, INC. 0.56% 53.71 Delayed Quote.-9.55%
SANOFI 0.10% 103.72 Real-time Quote.16.98%
TESCO PLC -0.50% 257 Delayed Quote.-10.90%
UNILEVER PLC -1.26% 3496.5 Delayed Quote.-10.25%
All news about GLAXOSMITHKLINE PLC
05/24TRANSCRIPT : GSK plc Presents at UBS Global Healthcare Conference, May-24-2022 09:15 AM
CI
05/24European executives' confidence plunges on Ukraine crisis - survey
RE
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
MD
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
FA
05/18S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery
MT
05/17FTSE 100 lags European peers on strong pound
RE
05/17GlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
MT
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
RE
05/16GlaxoSmithKline Adopts Shortened GSK Name
MT
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2022 36 527 M 45 865 M 45 865 M
Net income 2022 5 289 M 6 641 M 6 641 M
Net Debt 2022 17 655 M 22 168 M 22 168 M
P/E ratio 2022 16,7x
Yield 2022 2,96%
Capitalization 89 836 M 113 B 113 B
EV / Sales 2022 2,94x
EV / Sales 2023 2,79x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 775,00 GBX
Average target price 1 865,77 GBX
Spread / Average Target 5,11%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC10.92%112 914
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494